Free Trial

Altimmune (ALT) Competitors

Altimmune logo
$6.49 +0.12 (+1.82%)
Closing price 03:59 PM Eastern
Extended Trading
$6.49 +0.00 (+0.06%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALT vs. SDGR, NAMS, APGE, BLTE, TVTX, IRON, IOVA, EVO, WVE, and PRAX

Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Schrödinger (SDGR), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Belite Bio (BLTE), Travere Therapeutics (TVTX), Disc Medicine (IRON), Iovance Biotherapeutics (IOVA), Evotec (EVO), Wave Life Sciences (WVE), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

Altimmune vs.

Schrödinger (NASDAQ:SDGR) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Altimmune received 5 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 73.75% of users gave Altimmune an outperform vote while only 57.45% of users gave Schrödinger an outperform vote.

CompanyUnderperformOutperform
SchrödingerOutperform Votes
54
57.45%
Underperform Votes
40
42.55%
AltimmuneOutperform Votes
59
73.75%
Underperform Votes
21
26.25%

Schrödinger has higher revenue and earnings than Altimmune. Schrödinger is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$216.67M8.75$40.72M-$2.34-11.12
Altimmune$430K1,072.75-$88.45M-$1.55-4.18

Schrödinger has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.

Schrödinger presently has a consensus price target of $32.11, suggesting a potential upside of 23.46%. Altimmune has a consensus price target of $20.83, suggesting a potential upside of 221.20%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Schrödinger.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Schrödinger
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.80
Altimmune
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

Schrödinger has a net margin of -91.84% compared to Altimmune's net margin of -199,076.92%. Schrödinger's return on equity of -35.77% beat Altimmune's return on equity.

Company Net Margins Return on Equity Return on Assets
Schrödinger-91.84% -35.77% -24.51%
Altimmune -199,076.92%-55.81%-50.60%

In the previous week, Schrödinger had 1 more articles in the media than Altimmune. MarketBeat recorded 4 mentions for Schrödinger and 3 mentions for Altimmune. Altimmune's average media sentiment score of 1.29 beat Schrödinger's score of 0.81 indicating that Altimmune is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Schrödinger
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Altimmune
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

79.1% of Schrödinger shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 8.6% of Schrödinger shares are held by insiders. Comparatively, 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Schrödinger beats Altimmune on 9 of the 17 factors compared between the two stocks.

Get Altimmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALT vs. The Competition

MetricAltimmunePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$461.28M$6.90B$5.77B$9.20B
Dividend YieldN/A2.90%5.25%3.99%
P/E Ratio-4.189.4226.4419.50
Price / Sales1,072.75277.40456.0271.28
Price / CashN/A75.4646.0638.90
Price / Book2.365.477.255.07
Net Income-$88.45M$123.25M$3.19B$222.54M
7 Day Performance3.12%2.36%2.13%2.29%
1 Month Performance-5.45%1.37%3.49%1.63%
1 Year Performance-25.96%-0.12%21.19%16.61%

Altimmune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALT
Altimmune
2.831 of 5 stars
$6.49
+1.8%
$20.83
+221.2%
-27.3%$461.28M$430,000.00-4.1850Short Interest ↓
Positive News
SDGR
Schrödinger
1.4344 of 5 stars
$25.34
-1.3%
$32.11
+26.7%
-23.5%$1.85B$216.67M-10.84790Gap Up
NAMS
NewAmsterdam Pharma
3.3833 of 5 stars
$19.41
-3.9%
$41.60
+114.3%
-3.9%$1.80B$14.09M0.004
APGE
Apogee Therapeutics
2.5624 of 5 stars
$39.45
-0.7%
$89.71
+127.4%
+1.7%$1.77BN/A-16.2191
BLTE
Belite Bio
3.3994 of 5 stars
$54.00
-6.1%
$96.33
+78.4%
+17.6%$1.68BN/A-49.0010Short Interest ↓
TVTX
Travere Therapeutics
2.4435 of 5 stars
$21.09
-3.0%
$24.00
+13.8%
+179.4%$1.64B$145.24M-4.63460
IRON
Disc Medicine
2.1135 of 5 stars
$54.93
+0.2%
$88.90
+61.8%
-17.9%$1.63BN/A-13.7830Short Interest ↑
IOVA
Iovance Biotherapeutics
4.3062 of 5 stars
$5.34
-6.2%
$22.69
+325.3%
-39.1%$1.63B$90.86M-3.58500
EVO
Evotec
1.5313 of 5 stars
$4.53
+1.7%
$5.93
+31.1%
-37.8%$1.60B$845.74M0.005,061
WVE
Wave Life Sciences
4.3085 of 5 stars
$10.51
-5.9%
$22.22
+111.4%
+176.5%$1.60B$53.61M-9.47240
PRAX
Praxis Precision Medicines
2.0197 of 5 stars
$85.13
-2.0%
$149.00
+75.0%
+117.1%$1.59B$2.45M-8.27110

Related Companies and Tools


This page (NASDAQ:ALT) was last updated on 2/18/2025 by MarketBeat.com Staff
From Our Partners